Whole genome sequencing, comprehensive genomic profiling, and spatial multiomics are transforming precision medicine from research tools to clinical applications in oncology, rare diseases, and neonatal care, enabling faster diagnoses and personalized treatments.
New research warns AI pathology systems may use statistical shortcuts rather than biological signals, while a clinical trial shows stereotactic radiation improves quality of life for patients with multiple brain metastases compared to whole brain radiation.
Lynch syndrome patients gain access to prevention vaccines in clinical trials, while immunotherapy advances depend on universal tumor testing for microsatellite instability. Cancer vaccines are moving from research to clinical reality.
Researchers at Stony Brook University developed an oral vaccine using modified Listeria monocytogenes that generates anti-tumor immune responses in the gut and significantly improves colorectal cancer control when combined with checkpoint inhibitors.
New research identifies circulating tumor-reactive T cell characteristics and inflammatory biomarkers as predictive indicators for immune checkpoint inhibitor response in cancer patients, while the PD-L1 testing market is projected to reach $36.44 billion by 2032.
